Humanized BCMA CAR-T cell therapy for relapse or refractory multiple myeloma

Conditions

Relapse or refractory multiple myeloma

Li X, Can Liu, Siyan Niu, Ru Li, Shuquan Gao et al. (10 authors)

Journal of Translational Medicine2026-05-25

Correlation between the expression of soluble BCMA and short-term/long-term curative effect and survival outcomes of anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma

Mingwei Fu, Siqi Niu, Can Liu, Juan Mu, Shuquan Gao et al. (8 authors)

Cell Transplantation2025-09-01

10.1177/09636897251374203

Efficacy and follow‐up of humanized anti‐BCMA CAR‐T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary‐extraosseous, extramedullary‐bone related, and without extramedullary disease

Wei Li, Meijing Liu, Ting Yuan, Lixiang Yan, Rui Cui et al. (6 authors)

Hematological Oncology2021-12-2325 citations

10.1002/hon.2958

Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease

Haobin Deng, Meijing Liu, Ting Yuan, Huan Zhang, Rui Cui et al. (10 authors)

Frontiers in Immunology2021-08-0553 citations

10.3389/fimmu.2021.720571

Interventions

Group 1:Humanized BCMA CAR-T treatment

Group 2:Humanized BCMA CAR-T treatment for murine BCMA CAR-T treatment failure

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients or legal guardians sign informed consent; 2. Male or female patients aged 18-85 (including 18 and 85 years); 3. The patients who were diagnosed as multiple myeloma by cell morphology and flow cytometry were found to have poor curative effect after receiving the standard treatment plan, and were diagnosed as relapsed refractory multiple myeloma. 4. Patients with measurable or evaluable lesions; 5. The function of main tissues and organs of the patient is good: (1) Liver function: ALT / AST = 95%; (4) Cardiac function: left ventricular ejection fraction (LVEF) >= 40%. 6. Patients whose peripheral superficial vein blood flow is unobstructed and can meet the needs of intravenous drip; 7. Patients with Karnofsky score >= 60.

Exclusion criteria

Exclusion criteria: 1. Women in pregnancy (positive urine / blood pregnancy test) or lactation; 2. Men or women who have pregnancy plans in the past year; 3. The patients can not guarantee to take effective contraceptive measures (condoms or contraceptives, etc.) within one year after entering the group; 4. Patients with uncontrollable infectious diseases within 4 weeks before enrollment; 5. HIV infected patients; 6. Patients with primary tumors other than B-cell lymphoma diagnosed by pathology; 7. Patients with serious autoimmune diseases or immunodeficiency diseases; 8. Patients with allergic constitution are allergic to macromolecular biological drugs such as antibodies or cytokines; 9. Patients who participated in other clinical trials within 6 weeks before admission; 10. Patients who systematically used hormone within 4 weeks before admission (except those who used inhaled hormone); 11. Patients with mental illness; 12. Patients with drug abuse / addiction; 13. According to the judgment of the researcher, other patients are not suitable for the group.

Design outcomes

Primary

Measure	Time frame
remission rate;	—

Secondary

Measure	Time frame
Progression-free survival;Overall survival;	—

Countries

China

Contacts

Public ContactDeng Qi

Tianjin First Central Hospital

kachydeng@hotmail.com+86 13612055872

Outcome results

None listed